Articles tagged with Hematopoietic Stem Cells
Researchers have successfully used a genetic vector to efficiently transduce bone marrow cells from SCD patients, suggesting a potential treatment method. The study's findings support the use of autologous HSC transplant with genetically modified patient cells to treat sickle cell disease.
Researchers at Mount Sinai have made a breakthrough in programming blood-forming stem cells, which could lead to the development of patient-specific blood products. The study uses mouse fibroblast cells and identifies a combination of four genetic factors that can generate blood vessel precursor cells with hematopoietic cells.
Researchers identified unique properties of normal MLL1 pathway in hematopoietic stem cells that may be exploited to treat leukemia with MLL1 translocations. This could lead to improved transplantation outcomes for chemotherapy-resistant cancers.
Dr. Jennifer Gillette is studying the role of hematopoietic stem cells in directing the creation of new blood vessels at the site of a crisis, such as a heart attack. Her research aims to improve treatment responses for heart disease and potentially benefit cancer patients who receive hematopoietic stem cell transplants.
Researchers discovered that discarded immune cells stimulate the release of hematopoietic stem cells from the bone marrow into the bloodstream. This process is regulated by the daily elimination of neutrophils and follows a circadian cycle, which could have implications for cardiovascular health.
A team of Caltech biologists found that microRNA-146a acts as a critical regulator and protector of blood-forming stem cells during chronic inflammation. Mice lacking miR-146a showed a decline in HSCs, while normal mice maintained their levels despite long-term inflammation.
Researchers at Memorial Sloan-Kettering Cancer Center have discovered that expression of TRAIL in transplanted hematopoietic stem cells is critical for an effective anti-tumor response. This finding has led to the development of new therapeutic strategies to suppress graft-versus-host disease while maintaining anti-tumor activity.
Researchers have discovered that hematopoietic stem cells can perceive signals from the body during emergencies and produce specialized white blood cells, such as macrophages. This discovery could lead to new strategies for protecting patients undergoing bone marrow transplants from infections.
Researchers found that human hematopoietic stem cells can survive for longer periods when cultured with a feeder layer of adipocytes, or fat cells. The study demonstrates the potential for using fat cells to extend the lifespan of hHSCs in vitro, which could be crucial for developing advanced cell therapies.
Researchers at Weill Cornell Medicine developed a new method to expand adult hematopoietic stem cells outside the human body, overcoming a major technical hurdle. This breakthrough could lead to fewer donor cells being needed for transplantation and make bone marrow banking possible.
Researchers found that allogeneic hematopoietic stem cell transplantation with mesenchymal stem cells from third-party donors improved poor graft function in five patients with acute GVHD and two with chronic GVHD. The treatment also showed promise in reducing morbidity and mortality.
The study reveals that the Notch protein activates GATA2 gene to produce hematopoietic stem cells and regulates its expression through HES-1 repressor. This basic circuit is essential for generating limited production of GATA2, necessary for hematopoietic stem cell production.
A new study suggests that maintaining a healthy environment for haematopoietic stem cells (HSCs) is more effective than targeting leukaemia stem cells (LSCs). This approach could lead to earlier and more targeted treatment of leukaemia by reducing competition between healthy and cancerous cells.
A new study reveals cultural and social factors that hinder minority participation in stem cell donation, leading to lower patient success rates. Minority donors are more likely to opt-out due to concerns about health complications and mistrust of the medical system.
Researchers have made significant breakthroughs in optimizing stem cells and transplant approaches to treat patients with blood disorders. A new study has shown that the addition of vorinostat to standard therapy can safely reduce the incidence and severity of graft-versus-host disease, a life-threatening complication associated with h...
University of Rochester Medical Center scientists have discovered a new approach to speed up blood stem cell recovery after a vulnerable period following a stem-cell transplant. Prostaglandin E2 boosts blood production and protects the surrounding microenvironment, offering new hope for patients with leukemia or other blood disorders.
Researchers at the Medical University of South Carolina found that saturated fatty acids and specific metabolic pathways contribute to diabetic cardiomyopathy in mice. Additionally, a study published by Helen Hobbs' group identified the mutation PNPLA3 as a contributing factor to non-alcoholic fatty liver disease in mice.
The Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research at Albert Einstein College of Medicine hosted its first stem cell institute symposium, showcasing the latest research on induced pluripotent stem cells and hematopoietic stem cells. The event featured four presentations by renowned speakers fr...
Researchers develop a non-invasive method to track Huntington's disease progression by detecting mutant huntingtin protein in immune cells. Additionally, CXCR1/2 inhibition improves pancreatic islet survival after transplantation, and the loss of thyroid stimulating hormone contributes to osteoporosis.
Dr. Margaret A. Goodell is awarded the 2012 William Dameshek Prize for her groundbreaking work on hematopoietic stem cells and their role in regulating the immune response.
Researchers from IMIM have deciphered the role of β-catenin in generating haematopoietic stem cells, which can be used to treat leukaemia patients without compatible donors. The study lays the foundation for laboratory-generated stem cells that can improve transplant quality and quantity.
Researchers have identified a molecular cue that maintains a quiescent pool of blood-forming stem cells in mouse bone marrow by regulating non-canonical Wnt-signaling. The study found that Flamingo and Frizzled 8 play a crucial role in maintaining the balance between long-term maintenance and ongoing tissue maintenance and regeneration.
Scientists at Cincinnati Children's Hospital Medical Center have found that inhibiting the protein Cdc42 can reverse the aging of hematopoietic stem cells, restoring their functional efficiency. This breakthrough has significant implications for understanding and combating age-related diseases.
A team led by Nancy Speck at the University of Pennsylvania School of Medicine has discovered a molecular marker for hematopoietic stem cells, providing insights into their origin and development. This finding could help manipulate embryonic stem cells to generate new blood cells for therapy in leukemia patients
Researchers studied hematopoietic stem cells in healthy young and elderly individuals, finding that older stem cells produce fewer lymphocytes and more myeloid cells. This bias may lead to inadequate immune responses and increased risk of blood cancers.
Researchers created a novel 3D long-term bone marrow culture system to investigate stromal cell biological function. This system successfully maintained hematopoietic stem cells (HSCs) for extended periods, enabling the analysis of stromal-cell interactions and regulatory factors.
A new regimen of conditioning therapy before stem cell transplant has improved survival outcomes for older patients with hematologic malignancies. The study found that 5-year overall survival rates were around 35%, and progression-free survival rates were around 32%.
Researchers successfully expanded hematopoietic stem cells a hundredfold by understanding the molecular mechanisms of self-renewal. The study reveals that proliferation, suppression of differentiation and programmed cell death are required for self-renewal.
Researchers from Lund University have developed a method using ultrasound to improve the quality of transplanted blood stem cells. This improvement could lead to better treatment outcomes and reduced risk of graft-versus-host disease and infections.
For the first time, researchers have successfully injected cultured red blood cells (cRBCs) created from human hematopoietic stem cells (HSCs) into a human donor. The cRBCs were capable of progressing through the full maturation process and demonstrated survival rates comparable to conventional native red blood cells.
Research suggests that blood stem cells may play a role in the development of chronic lymphocytic leukemia (CLL), a cancer of mature white blood cells. CLL often begins with an asymptomatic proliferation of B cells called monoclonal B lymphocytosis (MBL). The study found that hematopoietic stem cells, which can give rise to any type of...
Researchers found that growing blood stem cells for about a week can improve transplantation success rates by reducing immune rejection. The lab-grown HSCs produce an immune system inhibitor on their surface, making them less likely to be rejected and more likely to engraft into the recipient's blood.
Scientists at the Salk Institute developed a new technique to generate large numbers of blood cells from patient cells, improving efficiency by 84% compared to previous methods. However, further refinements are needed to produce transplantable HSCs.
Researchers at UCSD have discovered a novel signaling pathway and gene, Wnt16, essential for the formation of hematopoietic stem cells in vertebrate embryos. This breakthrough has significant implications for developing stem cell-based therapies for diseases such as leukemia.
A UBC-led team has developed an automated microfluidic cell culture platform to study hundreds of hematopoietic stem cells at the single cell level. The new tool provides insights into HSC survival and growth factor requirements, with applications in drug development, clone selection, and culture optimization.
Researchers developed an effective gene therapy technique using induced pluripotent stem cells to correct chronic granulomatous disease in cell culture. The corrected neutrophils produced normal levels of hydrogen peroxide, potentially offering a cure for the rare disorder.
Researchers found that hematopoietic stem cells can shift between rapidly dividing and dormant states, suggesting a more equal sharing of blood cell production burden. This adaptability allows cells to respond quickly to life-threatening situations, such as bacterial infections.
A team of researchers has identified a potential biomarker for predicting future metastasis in patients with the most common form of liver cancer. They also explored a new gene therapy approach to treating the underlying cause of most forms of muscular dystrophy.
A study published in Blood demonstrates that newborn screening and early diagnosis of Severe Combined Immunodeficiency (SCID) can improve survival rates. Babies diagnosed at birth and receiving a hematopoietic stem cell transplant have significantly reduced infections and improved survival outcomes.
Researchers at UC Santa Cruz identified a crucial molecule for blood stem cells' niche in the bone marrow, potentially improving transplant safety and efficiency. The study's findings may lead to safer and more effective treatment options for cancers like lymphoma and leukemia.
The American Society of Hematology awards $100,000 to fellows and $150,000 to junior faculty for a two- to three-year research period. The 2011 Scholar Award recipients include Basic Research Fellow Omar I. Abdel-Wahab, MD, and Clinical/Translational Research Fellow Samantha M. Jaglowski, MD.
Researchers at Indiana University School of Medicine introduce a potent anti-tumor gene into mice with metastatic melanoma, resulting in complete remission and permanent immune reconfiguration. The gene therapy uses modified lentivirus to deliver a T cell receptor gene that recognizes specific melanoma proteins.
The Georgia Tech-led Nanomedicine Center plans to pursue a clinically viable gene correction technology for single-gene disorders, including sickle cell disease. The team aims to deliver engineered zinc finger nucleases and DNA correction templates into hematopoietic stem cells to produce healthy red blood cells.
Researchers at Rockefeller University identified a gene called Sept4 that regulates programmed cell death in precursor cells, which can increase the risk of developing cancer. The study found that mice lacking the Sept4 gene had twice as many hematopoietic stem cells and were more susceptible to tumors.
Researchers at Cincinnati Children's Hospital Medical Center identified a molecular communications pathway influencing hematopoietic stem cell mobilization. Pharmacological inhibition of the Egfr signaling pathway increased stem cell mobilization in mice, suggesting a new rationale for targeted therapies.
Researchers have discovered unique metabolic properties of bone-marrow stem cells that allow them to survive and replicate in low-oxygen environments. This finding may lead to new strategies for enriching stem cells by selecting those with specific metabolic characteristics.
Researchers found that MSCs create a supportive niche for HSCs, allowing them to self-renew and develop into blood cells. Altering MSC numbers affects HSC population, suggesting a regulatory interaction between the two cell types.
Researchers at Caltech have identified a novel group of microRNAs that regulate the production of hematopoietic stem cells, which produce blood cells. The study found that one particular miRNA enhances the production of mature blood cells but can also induce aggressive leukemia when overexpressed.
Researchers from Massachusetts General Hospital identified a microRNA molecule that increases the number of hematopoietic stem cells, which can give rise to all blood and immune system cells. This discovery may lead to improved cancer treatment by expanding stem cell populations.
Researchers at the University of Montreal have identified three proteins that regulate blood cell production and one protein that inhibits it. Understanding these factors is crucial for developing novel therapies to treat diseases caused by abnormal blood-making stem cells.
Scientists found that p53 loss enables aberrant self-renewal of myeloid precursors, leading to acute myeloid leukemia. In experiments with living mice, the team demonstrated that a combination of p53 and Kras mutations confers resistance to chemotherapy and promotes aggressive AML.
Researchers found that gamma interferon prompts the activation of hematopoietic stem cells, which produce immune system cells to combat infections. Chronic infections like tuberculosis and HIV/AIDS may lead to bone marrow exhaustion due to sustained activity by these stem cells.
Researchers used systems biology approaches to study how hematopoietic cells react to high levels of erythropoietin. They found that the cells rapidly take up and break down the hormone, replenishing their receptors in a continuous process. This understanding may lead to developing more effective anemia treatments.
Researchers at Rice University and the University of Cambridge have created a computer model that accurately describes the behavior of three regulatory proteins in hematopoietic stem cells. The Scl-Gata2-Fli1 triad is thought to be the master-level regulator for these self-renewing cells, which produce new blood cells.
A study examining global hematopoietic stem cell transplantation (HSCT) rates found significant differences in transplant use between countries and regions. HSCT is most frequently used in countries with higher gross national incomes and governmental healthcare expenditures.
A study published in Journal of Experimental Medicine identifies distinct HSC populations with varying propensities to generate specific blood cell types. The research reveals that high CD150 expression is associated with a 'latent' or 'delayed' ability to generate new blood cells.
Researchers at UTHealth are developing new strategies to derive hematopoietic stem cells from pluripotent stem cells, which could potentially treat blood diseases. Additionally, they are exploring gene-corrected induced pluripotent stem cells for treating two pediatric lung diseases, Surfactant Protein B Deficiency and Cystic Fibrosis.
Researchers discover a commercially available supplement stimulates production of hematopoietic stem cells, repairing the body. The supplement increases levels of these cells in the blood over a two-week period, showing potential for treating conditions associated with low cell counts.
Researchers at Baylor College of Medicine report that hematopoietic stem cell subtypes exist and act as previously thought, contradicting the idea of a single stem cell giving rise to all types of blood cells. The study reveals distinct populations of stem cells over time, with implications for treatment.
Researchers at UC San Diego have identified the region in vertebrates where adult blood stem cells arise during embryonic development. This discovery is a critical step towards developing safer and more effective stem cell therapies for patients with leukemia, multiple myeloma, and other diseases.